Viagenpumatucel-L: Phase Ib/II resumed

Heat Biologics resumed enrollment in the Phase Ib portion of the open-label, U.S. Phase Ib/II DURGA trial evaluating once-weekly injections of 1x10 7 cells of HS-110 for 18 weeks plus Opdivo nivoluma...